Serum hepatitis and infectious hepatitis now constitute the main hazard of the transfusion of blood and certain blood products (Zuckerman, 1968) . Mosley (1965) classified human blood and blood derivatives according to the risk of post-transfusion hepatitis as 'average-risk' materials, which include fresh blood and single donor plasma, 'high-risk' derivatives, which include pooled plasma, fibrinogen, and antihaemophilic globulin, and 'safe' products such as pooled immunoglobulin (gamma globulin) and appropriately treated serum albumin, stable plasma protein solution, fibrin foam, and plasminogen. It should be noted that the risk of hepatitis associated with untreated blood products is independent of the method of fractionation of blood by cold ethanol, by cold ether, or by ammonium sulphate precipitation.
There is extensive epidemiological and immunological evidence for the existence of at least two forms of viral hepatitis and the discovery of the association between the Australia (hepatitis-associated) antigen (Blumberg, Gerstley, Hungerford, London, and Sutnick, 1967) and hepatitis has provided laboratory tests for an antigen which is specifically related to serum hepatitis or type B viral hepatitis (Zuckerman, 1970a) . It now appears likely that the Australia (hepatitis-associated) antigen is not the actual infectious agent but that it may Received for publication 18 November 1970. represent incomplete virus particles, or aggregates of protein subunits, or that the antigen is simply a protein which is produced specifically in the liver or at some other site in response to infection by the serum hepatitis virus (Zuckerman, 1970b; Zuckerman, Taylor, and Bird, 1970) . Nevertheless, the presence of the antigen in blood and blood fractions may serve as an indicator of potential infectivity with type B viral hepatitis, although the sensitivity of the available techniques does not yield an absolute measure of such risk (Barker, Shulman, Murray, Hirschman, Ratner, Diefenbach, and Geller, 1970 Zuckerman and The Australia (hepatitis-associated) antigen in fibrinogen and other fractions of human plasma Taylor (1969) after the method of Prince (1968) . The samples were prepared for examination by negative staining in the electron microscope by the method described in detail elsewhere (Zuckerman, 1970c In the past the assessment of risk involved in the use of fibrinogen proved difficult because fibrinogen is generally given with whole blood. Attack rates of 14 to 15% were reported by Phillips (1965) and 17% by an expert committee (WHO, 1964) . In two university hospitals in the United States it was estimated that the proportion of fibrinogen recipients amongst patients with transfusion-associated hepatitis was 35 times greater than amongst patients transfused with blood only (Mosley, 1965) . Only rarely does a situation arise, apart from specific deficiency of fibrinogen or antihaemophilic globulin, in which fibrinogen is required without a need for blood or plasma as well. Mosley (1965) mentions the occurrence of hepatitis in six of 21 patients following the administration of fibrinogen alone. The more recent introduction of radioiodinated fibrinogen (1251) for the diagnosis of deep vein thrombosis (Browse, 1969) has introduced a new risk. The enthusiastic use of 1251-fibrinogen for diagnostic procedures should be assessed against the possible risk of hepatitis. Indeed serum hepatitis associated with the Australia antigen has already been reported in two patients from the west of Scotland who had been injected with 1251-fibrinogen (Laiwah, Goudie, Goldberg, Davidson, and Murray, 1970) .
The availability of specific serological methods in Fig. 1 
